USA - NASDAQ:FTRE - US34965K1079 - Common Stock
The current stock price of FTRE is 10.03 USD. In the past month the price increased by 4.48%. In the past year, price decreased by -40.47%.
|  Symbol  |  Company Name  |  TA  |  FA  |  PE  |  Market Cap  | 
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.83 | 210.03B | ||
| DHR | DANAHER CORP | 27.89 | 153.99B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 143.51 | 46.81B | ||
| A | AGILENT TECHNOLOGIES INC | 26.3 | 40.64B | ||
| IQV | IQVIA HOLDINGS INC | 18.61 | 36.80B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.67 | 28.37B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.4 | 20.03B | ||
| WAT | WATERS CORP | 28.04 | 20.41B | ||
| MEDP | MEDPACE HOLDINGS INC | 40.59 | 16.30B | ||
| TEM | TEMPUS AI INC | N/A | 14.99B | ||
| ILMN | ILLUMINA INC | 23.8 | 15.22B | ||
| ICLR | ICON PLC | 12.53 | 12.86B | 
 Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 14,500 full-time employees. The company went IPO on 2023-06-16. The firm is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The firm offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The firm manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The firm has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
FORTREA HOLDINGS INC
8 Moore Drive
Durham NORTH CAROLINA US
Employees: 14500
Phone: 18774950816
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 14,500 full-time employees. The company went IPO on 2023-06-16. The firm is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The firm offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The firm manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The firm has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
The current stock price of FTRE is 10.03 USD. The price decreased by -3.93% in the last trading session.
FTRE does not pay a dividend.
FTRE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
FORTREA HOLDINGS INC (FTRE) operates in the Health Care sector and the Life Sciences Tools & Services industry.
FORTREA HOLDINGS INC (FTRE) has a market capitalization of 910.72M USD. This makes FTRE a Small Cap stock.
FORTREA HOLDINGS INC (FTRE) will report earnings on 2025-11-05, before the market open.
ChartMill assigns a technical rating of 9 / 10 to FTRE. When comparing the yearly performance of all stocks, FTRE is one of the better performing stocks in the market, outperforming 81.16% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to FTRE. FTRE may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months FTRE reported a non-GAAP Earnings per Share(EPS) of 0.62. The EPS increased by 72.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.22% | ||
| ROE | -174.29% | ||
| Debt/Equity | 1.87 | 
16 analysts have analysed FTRE and the average price target is 7.8 USD. This implies a price decrease of -22.2% is expected in the next year compared to the current price of 10.03.
For the next year, analysts expect an EPS growth of 66.4% and a revenue growth -2.39% for FTRE